Investigational drug · Phase 2
WSD0922-FU
Also called: WSD0922
Not approved by FDA. In 3 industry-sponsored Phase 2 or 3 trials that are active or finished in the last two years, most often for Non Small Cell Lung Cancer (NSCLC), EGFR Mutation Positive Advanced Non-Small Cell Lung Cancer, Non Small Cell Lung Cancer.
Phase 2Last checked: Nov 19, 2026Latest source record: Nov 12, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 2
Industry-sponsored trials
Phase 2 and 3 trials
3
3 still active
All registered trials
6
Any phase or sponsor naming "WSD0922-FU"
First trial start
2024
Sep 4, 2024
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "WSD0922-FU", any sponsor or status.
Conditions studied
As listed on its trial records.
- Non Small Cell Lung Cancer (NSCLC)
- EGFR Mutation Positive Advanced Non-Small Cell Lung Cancer
- Non Small Cell Lung Cancer
Approved drugs for the same conditions: Non-small cell lung cancer · Small cell lung cancer · Oncology
Largest trials
Live from ClinicalTrials.gov: studies naming "WSD0922-FU" as an intervention, largest first.
- A Phase III Study of WSD0922-FU Versus Chemotherapy In Patients With C797S+ Advanced Non-small Cell Lung CancerPivotal-lookingNot yet recruiting
Wayshine Biopharm, Inc.Industry
NCT07948408 · 196 participants (planned) · Start Dec 10, 2026 · Primary completion May 1, 2028
Drug: WSD0922-FU; Platinum-based doublet chemotherapy (Pemetrexed and Cisplatin or Carboplatin) · For: Non Small Cell Lung Cancer (NSCLC)
Sites: Shanghai, China
- A Study to Assess the Efficacy and Safety of WSD0922-FU in Patients With EGFRm+ Advanced Non-small Cell Lung CancerActive, not recruiting
Wayshine Biopharm, Inc.Industry
NCT06631989 · 60 participants · Start Sep 4, 2024 · Primary completion Jun 30, 2027
Drug: WSD0922-FU · For: EGFR Mutation Positive Advanced Non-Small Cell Lung Cancer
Sites: Hefei, China; Beijing, China; Guangzhou, China · 12 sites in all
Mayo ClinicAcademic, hospital or other
NCT07708961 · 60 participants (planned) · Start Aug 28, 2026 · Primary completion Aug 31, 2036
Drug: EGFR/EGFRvIII Inhibitor WSD0922-FU; Temozolomide · For: Glioblastoma, IDH-Wildtype
Sites: Scottsdale, Arizona; Jacksonville, Florida; Rochester, Minnesota
- WSD0922-FU for Treatment of Glioblastoma, Anaplastic Astrocytoma, or Non-small Cell Lung Cancer With Central Nervous System MetastasesActive, not recruiting
Mayo ClinicAcademic, hospital or other
NCT04197934 · 56 participants · Start Dec 20, 2019 · Primary completion Oct 30, 2022
Drug: EGFR/EGFRvIII Inhibitor WSD0922-FU · For: Anaplastic Astrocytoma, IDH-Wildtype; Glioblastoma, IDH-Wildtype; Metastatic Lung Non-Small Cell Carcinoma and 2 more
Sites: Scottsdale, Arizona; Jacksonville, Florida; Rochester, Minnesota
Wayshine Biopharm, Inc.Industry
NCT07206498 · 48 participants (planned) · Start Oct 17, 2025 · Primary completion Oct 14, 2028
Drug: Osimertinib (Tagrisso®); WSD0922-FU · For: Non Small Cell Lung Cancer (NSCLC)
Sites: Fuzhou, China; Tianjin, China; Shanghai, China
Wayshine Biopharm, Inc.Industry
NCT06868485 · 40 participants (planned) · Start Aug 18, 2025 · Primary completion Sep 30, 2027
Drug: WSD0922-FU Tablets, Dose level A; WSD0922-FU Tablets, Dose level B · For: Non Small Cell Lung Cancer
Sites: Weston, Florida; Manahawkin, New Jersey; Cleveland, Ohio · 16 sites in all
Newest research
PubMed records naming it or its code names, newest first.
- WSD-0922, a novel brain-penetrant inhibitor of epidermal growth factor receptor, promotes survival in glioblastoma mouse models.
Conage-Pough JE, Stopka SA, Oh JH, et al. · Neurooncol Adv 2023
Also in development for Non Small Cell Lung Cancer (NSCLC)
- JSKN033Phase 34 trials
Jiangsu Alphamab Biopharmaceuticals Co., Ltd · Cervical Cancer, Recurrent or Metastatic Cervical Cancer, Advanced Malignant Tumors
- LS301-ITPhase 22 trials
Integro Theranostics · Non Small Cell Lung Cancer (NSCLC), Breast Cancer, DCIS
- AP203Phase 21 trial
AP Biosciences Inc. · Locally Advanced or Metastatic Solid Tumors, Non Small Cell Lung Cancer (NSCLC), Head and Neck Squamous Cell Carcinoma (HNSCC)
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.